Company intelligence / Profile preview

AxoSim

New Orleans, Louisiana, United Statesaxosim.com ↗

Ownership: Private
Employees: ~39
Development stage: Commercial

Overview

AxoSim provides advanced human-relevant neurodiscovery platforms that deliver clinically relevant data to improve the selection of lead candidates in neurological drug development. Their nerve-on-a-chip and brain organoid systems enable more predictive safety and efficacy screening than traditional animal models. The company’s technology has been validated through grants from NIH and NSF, with applications demonstrated in peripheral neuropathy, neurodegeneration, and neurotoxicology studies.

Therapeutic areas: Neurology
Modalities: Device (Organ-on-a-chip)3D Cell AssaysMicrophysiological system (MPS) organoid technologiesDisease modeling platforms (Nerve-on-a-Chip, BrainSim®, microBrain™)
Industry: Non-Drug Biotech

Partnerships

Not explicitly listed; works with biopharma clients as CRO/service provider.

Beyond the preview

Go deeper on AxoSim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AxoSim.

Explore the full profile